← All trials
NCT04917718
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jun 8, 2021
- Last posted
- Jun 14, 2021
- Enrollment
- 42
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Loyola UniversityLead sponsor
- Loyola UniversityReponsible party - principal investigator
- Loyola UniversityOverall official - principal investigator
- Veloxis PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.